Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Benzinga Newsdesk 3 months ago
NewsGuidanceHot
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.